+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

  • Mar 22, 2023: Gilead Sciences announces $3 Million in grant funding to eight organizations addressing HIV Disparities in Rural U.S. Communities
  • Mar 21, 2023: Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader
  • Mar 02, 2023: Gilead Foundation Donating $1 Million for Relief Efforts in Türkiye and Syria
  • Feb 21, 2023: Gilead presents new data from HIV cure research program and collaborations exploring novel investigational combinations and strategies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Gilead Sciences Inc - Key Facts
  • Gilead Sciences Inc - Key Employees
  • Gilead Sciences Inc - Key Employee Biographies
  • Gilead Sciences Inc - Major Products and Services
  • Gilead Sciences Inc - History
  • Gilead Sciences Inc - Company Statement
  • Gilead Sciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Gilead Sciences Inc - Business Description
  • Product Category: Cell Therapy Products
  • Overview
  • Performance
  • Product Category: HBV Products
  • Overview
  • Performance
  • Product Category: HCV Products
  • Overview
  • Performance
  • Product Category: HIV Products
  • Overview
  • Performance
  • Product Category: Other Products
  • Overview
  • Performance
  • Product Category: Royalty, Contract and Other Revenues
  • Performance
  • Product Category: Trodelvy
  • Overview
  • Performance
  • Product Category: Veklury
  • Overview
  • Performance
  • Product Category: HBV Products
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Other International
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Gilead Sciences Inc - Corporate Strategy
  • Gilead Sciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Gilead Sciences Inc - Strengths
  • Gilead Sciences Inc - Weaknesses
  • Gilead Sciences Inc - Opportunities
  • Gilead Sciences Inc - Threats
  • Gilead Sciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Gilead Sciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 22, 2023: Gilead Sciences announces $3 Million in grant funding to eight organizations addressing HIV Disparities in Rural U.S. Communities
  • Mar 21, 2023: Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader
  • Mar 02, 2023: Gilead Foundation Donating $1 Million for Relief Efforts in Türkiye and Syria
  • Feb 21, 2023: Gilead presents new data from HIV cure research program and collaborations exploring novel investigational combinations and strategies
  • Feb 15, 2023: Gilead to present data at APASL 2023 on effective models for monitoring and treating Hepatitis C and efficacy of antiviral treatments for hiv-1 and HBV-coinfected adults
  • Feb 14, 2023: Gilead demonstrates transformative potential impact of Antiviral Innovation at CROI 2023
  • Feb 02, 2023: Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
  • Feb 01, 2023: Gilead awards $7.6 million in grants to advance health equity in breast cancer
  • Jan 19, 2023: The Robert A. winn diversity in clinical trials award program established by the Bristol Myers Squibb foundation to expand with amgen’s commitment of $8 million
  • Jan 04, 2023: Gilead partners with EVOQ for RA and lupus immunotherapies
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Gilead Sciences Inc, Key Facts
  • Gilead Sciences Inc, Key Employees
  • Gilead Sciences Inc, Key Employee Biographies
  • Gilead Sciences Inc, Major Products and Services
  • Gilead Sciences Inc, History
  • Gilead Sciences Inc, Other Locations
  • Gilead Sciences Inc, Subsidiaries
  • Gilead Sciences Inc, Joint Venture
  • Gilead Sciences Inc, Key Competitors
  • Gilead Sciences Inc, Ratios based on current share price
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Interim Ratios
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Gilead Sciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Gilead Sciences Inc, Performance Chart (2018 - 2022)
  • Gilead Sciences Inc, Ratio Charts
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Islet Sciences Inc
  • Bristol-Myers Squibb India
  • Abbott Laboratories
  • S J Weaver Contracting Inc
  • Quanta BioDesign Ltd
  • Janssen Therapeutics
  • Precigen Inc
  • Pfizer Inc
  • Incyte Corp
  • GSK plc
  • Earth Science Tech Inc
  • Viracta Therapeutics Inc
  • Checkpoint Therapeutics Inc
  • Ocera Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Enzon Pharmaceuticals Inc
  • Johnson & Philips Electric Co., Ltd.
  • Intercept Pharmaceuticals Inc
  • Kineta Inc
  • United Therapeutics Corp
  • Celgene Corp
  • San Benito Smart Park LLC
  • Fab Colours
  • Nock Middle School
  • Merck & Co Inc
  • hVIVO Services Ltd
  • Actelion Pharmaceuticals US Inc
  • Vividion Therapeutics Inc
  • Precigen Inc
  • Pfizer Inc
  • Incyte Corp
  • GSK plc
  • Earth Science Tech Inc
  • Novartis AG
  • Enzon Pharmaceuticals Inc
  • Viracta Therapeutics Inc
  • Vividion Therapeutics Inc
  • Checkpoint Therapeutics Inc
  • Janssen Therapeutics
  • Nock Middle School
  • Yumanity Therapeutics Inc
  • Ocera Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • S J Weaver Contracting Inc
  • Quanta BioDesign Ltd
  • hVIVO Plc
  • Johnson & Philips Electric Co., Ltd.
  • Intercept Pharmaceuticals Inc
  • Islet Sciences Inc
  • United Therapeutics Corp
  • Celgene Corp
  • Merck & Co Inc
  • Actelion Pharmaceuticals US Inc
  • Bristol-Myers Squibb India
  • Abbott Laboratories
  • San Benito Smart Park LLC
  • Fab Colours